UEEC United Health Products, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · OTC · SEC CIK 1096938 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY55.4%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-884.9%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets2,330.7%
Debt / equity—
Current ratio0.01x
Interest coverage-4.35x
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-235.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $2,683 | $3,852 | $12,562 | $47,299 | $36,199 | $80,983 | $116,251 | $108,779 |
| SG&A expense | $148,135 | $162,998 | $253,019 | $217,424 | $207,845 | $187,373 | $1.37M | $676,619 |
| Operating income | -$150,818 | -$166,850 | -$265,581 | -$264,723 | -$244,044 | -$268,356 | -$1.49M | -$785,398 |
| Interest expense | $59,571 | $50,456 | $48,109 | $36,788 | $30,684 | $25,100 | $20,712 | $9,483 |
| Net income | -$185,268 | -$284,140 | -$315,842 | -$536,908 | -$296,459 | -$315,187 | -$1.54M | -$814,112 |
| EBITDA | -$149,805 | -$165,838 | -$264,568 | -$263,710 | -$243,032 | -$267,344 | -$1.49M | -$784,386 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | -0.01 | — |
| Weighted avg. shares (diluted) | 262.73M | 260.04M | 258.69M | — | 257.81M | 257.14M | 254.58M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5,588 | $24,495 | $1,029 | $65,249 | $18,376 | $225 | $4,914 | $168,883 |
| Inventory | — | — | — | — | — | — | — | $0 |
| Current assets | $27,382 | $64,664 | $47,200 | $105,392 | $43,129 | $21,111 | $35,082 | $191,683 |
| Intangibles | $21,262 | $22,275 | $23,287 | $24,300 | $25,313 | $26,325 | $27,337 | $28,350 |
| Total assets | $204,498 | $247,985 | $248,825 | $316,698 | $94,313 | $81,538 | $104,542 | $269,979 |
| Current liabilities | $4.27M | $4.19M | $4.19M | $4.05M | $2.01M | $1.90M | $1.81M | $1.64M |
| Long-term debt | — | — | — | — | $927,500 | $847,500 | — | — |
| Total debt | — | — | — | — | $927,500 | $847,500 | — | — |
| Total liabilities | $4.77M | $4.69M | $4.44M | $4.30M | $3.43M | $3.25M | $2.96M | $2.71M |
| Shareholders' equity | -$4.56M | -$4.44M | -$4.30M | -$3.98M | -$3.37M | -$3.19M | -$2.88M | -$2.46M |
| Net debt | — | — | — | — | $909,124 | $847,275 | — | — |
| Shares outstanding | 263.69M | 261.59M | 258.69M | 258.69M | 258.69M | 257.13M | 257.13M | 252.41M |
| Cash flow statement | ||||||||
| Operating cash flow | -$194,275 | -$138,013 | -$84,339 | -$553,127 | -$175,157 | -$184,689 | -$273,969 | -$181,438 |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $175,368 | $161,479 | $20,119 | $600,000 | $193,308 | $180,000 | $110,000 | $306,538 |
| Depreciation & amortization | $1,013 | $1,012 | $1,013 | $1,013 | $1,012 | $1,012 | $1,013 | $1,012 |
| Stock-based compensation | — | — | — | — | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.